In patients with NSCLC, gastric cancer, or bladder cancer treated with nivolumab or pembrolizumab, a greater decrease in sPD-L1 after four cycles of treatment correlated with a greater decrease in tumor size [85]. Here, SPDL1 is linked to neoplasm.